Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|July 29, 2014
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group ReportStanton Goldman, Lynette Smith, Paul Galardy, et al.
American Journal of Clinical Pathology|December 22, 2010
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximabPaul N Meyer, Kai Fu, Timothy Greiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolutionFrancesco d'Amore, Eric Chan, Javeed Iqbal, et al.
Journal of Surgical Oncology|March 2, 2021
Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in IndiaSubramanyeshwar Rao T, Kalidindi Venkata Vijaya Narsimha Raju, Sujit Chyau Patnaik, et al.
British Journal of Haematology|April 11, 2015
Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study ReportBruce Shiramizu, Stanton Goldman, Lynette Smith, et al.
Oncology (Williston Park, N.Y.)|August 20, 2025
A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and NeckOmar K Abughanimeh Mbbs, Nicole A Shonka Md, Jane Meza PhD, et al.
Cancer Letters|April 20, 2021
Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiringSanjib Chaudhary, Ramesh Pothuraju, Satyanarayana Rachagani, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
A Rigorous Multi-Laboratory Study of Known PDAC Biomarkers Identifies Increased Sensitivity and Specificity Over CA19-9 AloneBrian Haab, Lu Qian, Ben Staal, et al.
Cancer Letters|September 14, 2024
A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 aloneBrian Haab, Lu Qian, Ben Staal, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 26, 2020
Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastomaBrittany J Poelaert, Svetlana Romanova, Shelby M Knoche, et al.
Pageof 9